Anxiety disorders in the 21st century: Status, challenges, opportunities, and comorbidity with depression

American Journal of Managed Care

Volumn 11, Issue SUPPL. 12, 2005, Pages

  DeVane, C Lindsay ^a   Chiao, Evelyn ^a   Franklin, Meg ^a   Kruep, Eric J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ANXIETY DISORDER; ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; ELDERLY CARE; EVIDENCE BASED MEDICINE; HEALTH CARE UTILIZATION; HUMAN; INFORMED CONSENT; MANAGED CARE; MEDICAL DECISION MAKING; MEDICAL SERVICE; MEDICARE; PATIENT COMPLIANCE; PREVENTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; QUALITY CONTROL; SEDATION; SIDE EFFECT; SYMPTOM;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; COMORBIDITY; DEPRESSIVE DISORDER; HUMANS; MANAGED CARE PROGRAMS; PATIENT COMPLIANCE; PREVALENCE;

EID: 27544493554     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593-602.
2. Greenberg PE, Sisitsky T, Kessler RC, et al. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry. 1999;60:427-435.
3. DuPont RL, Rice DP, Miller LS, Shiraki SS, Rowland CR, Harwood HJ. Economic costs of anxiety disorders. Anxiety. 1996;2:167-172.
4. National Heart, Lung, and Blood Institute. Morbidity and Mortality: 2002 Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda, Md: National Institutes of Health, US Dept of Health and Human Services; 2004.
5. Arikian SR, Gorman JM. A review of the diagnosis, pharmacologie treatment, and economic aspects of anxiety disorders. Primary Care Companion J Clin Psychiatry. 2001;3:110-117.
6. Schmitz N, Kruse J. The relationship between mental disorders and medical service utilization in a representative community sample. Soc Psychiatry Psychiatr Epidemiol. 2002;37:380-386.
7. Katon W. Panic disorder: relationship to high medical utilization, unexplained physical symptoms, and medical costs. J Clin Psychiatry. 1996;57(suppl 10):11-18.
8. Culpepper L. Use of algorithms to treat anxiety in primary care. J Clin Psychiatry. 2003;64(suppl 2):30-33.
9. Flint A. Generalized anxiety disorder in elderly patients: epidemiology, diagnosis and treatment options. Drugs Aging. 2005;22:101-114.
10. Mulsant BH, Reynolds CF 3rd, Shear MK, Sweet RA, Miller M. Comorbid anxiety disorders in late-life depression. Anxiety. 1996;2:242-247.
11. Lenze EJ, Mulsant BH, Shear MK, et al. Comorbid anxiety disorders in depressed elderly patients. Am J Psychiatry. 2000;157:722-728.
12. National Institute of Mental Health. Facts about anxiety disorders. Available at: http://www.nimh.nih.gov/publicat/adfacts.cfm. Accessed September 6, 2005.
13. American Psychiatric Association. Anxiety disorders. In: Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC: American Psychiatric Association; 2000:429-484.
14. Stein MB. Attending to anxiety disorders in primary care. J Clin Psychiatry. 2003;64(suppl 15):35-39.
15. Blanco C, Raza MS, Schneier FR, Liebowitz MR. The evidence-based pharmacological treatment of social anxiety disorder. Int J Neuropsychopharmacol. 2003;6:427-442.
16. Sramek JJ, Zarotsky V, Cutler NR. Generalised anxiety disorder: treatment options. Drugs. 2002;62:1635-1648.
17. Khonzam HR. Obsessive-compulsive disorder: what to do if you recognize baffling behavior. Postgrad Med. 1999;106:133-141.
18. Beekman AT, de Beurs E, van Balkom AJ, Deeg DJ, van Dyck R, van Tilburg W. Anxiety and depression in later life: co-occurrence and communality of risk factors. Am J Psychiatry. 2000;157:89-95.
19. Sheehan DV, Eaddy M, Shah MB, Mauch RP. Differences in total medical costs across the SSRIs for the treatment of depression and anxiety. Am J Manag Care. 2005;11:S354-S361.
20. Roy-Byrne PP, Katon W, Cowley DS, Russo J. A randomized effectiveness trial of collaborative care for patients with panic disorder in primary care. Arch Gen Psychiatry. 2001;58:869-876.
21. Roy-Byrne PP, Craske MG, Stein MB, et al. A randomized effectiveness trial of cognitive behavior therapy and medication for primary care panic disorder. Arch Gen Psychiatry. 2005;62:290-298.
22. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry. 2002;3:171-199.
23. Rouillon F. Long term therapy of generalized anxiety disorder. Eur Psychiatry. 2004;19:96-101.
24. Rickeis K, Schweizer E, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry. 1990;47:899-907.
25. DeVane CL, Pollock BG. Pharmacokinetic considerations of antidepressant use in the elderly. J Clin Psychiatry. 1999;60(suppl 20):38-44.
26. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther. 1997;61:331-339.
27. Chutka DS, Takahashi PY, Hoel RW. Inappropriate medications for elderly patients. Mayo Clin Proc. 2004;79:122-139.
28. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of the Osteoporotic Fractures Research Group. N Engl J Med. 1995;332:767-773.
29. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA. 1989;262:3303-3307.
30. Paterniti S, DuFouil C, Alperovitch A. Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study. J Clin Psychopharmacol. 2002;22:285-293.
31. Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry. 2002;63(suppl 14):9-16.
32. Lauderdale SA, Sheikh JI. Anxiety disorders in older adults. Clin Geriatr Med. 2003;19:721-741.
33. Lader M. Treatment of anxiety. BMJ. 1994;309:321-324.
34. Steyer R. FDA rejects expanding Lexapro marketing. Available at: http://www.thestreet.com/mktwrm/stocks/biotech/10215442.html. Accessed August 15, 2005.
35. Eaddy M, Bramley T, Regan T. Time to antidepressant discontinuation: a comparison of controlled-release paroxetine and immediate-release selective serotonin reuptake inhibitors. Manag Care Interface. 2003;16:22-27.
36. Gorman JM. Treatment of generalized anxiety disorder. J Clin Psychiatry. 2002;63(suppl 8):17-23.
37. Sweet RA, Brown EJ, Heimberg RG, et al. Monoamine oxidase inhibitor dietary restrictions: what are we asking patients to give up? J Clin Psychiatry. 1995;56:196-201.
38. Yonkers KA, Dyck IR, Warshaw M, Keller MB. Factors predicting the clinical course of generalised anxiety disorder. Br J Psychiatry. 2000;176:544-549.
39. Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psych. 1998;55:1128-1132.
40. Claxton AJ, Li Z, McKendrick J. Selective serotonin reuptake inhibitor treatment in the UK: risk of relapse or recurrence of depression. Br J Psychiatry. 2000;177:163-168.
41. Eaddy M, Sarnes M, Regan T, Mauch R. Examining the relationship between length of selective serotonin reuptake inhibitor treatment and the risk of hospitalization in a naturalistic managed care setting. Poster presented at: the Academy of Managed Care Pharmacy Educational Conference; Baltimore, Md; October 13-16, 2004.
42. DeVane CL. Immediate-release versus conrolled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. J Clin Psychiatry. 2003;64(suppl 18):14-19.
43. Thompson D, Buesching D, Gregor KJ, et al. Patterns of antidepressant use and their relation to costs of care. Am J Manag Care. 1996;2:1239-1246.
44. Eaddy MT, Druss BG, Sarnes MW, Began TS, Frankum LE. Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy-results from a managed care administrative claims database. J Manag Care Pharm. 2005;11:145-150.
45. Steffens DC, McQuoid DR. Impact of symptoms of generalized anxiety disorder on the course of late-life depression. Am J Geriatr Psychiatry. 2005;13:40-47.
46. Ritchie K, Artero S, Beluche I, et al. Prevalence of DSM-IV psychiatric disorder in the French elderly population. Br J Psychiatry. 2004;184:147-152.
47. van Hout HP, Beekman AT, de Beurs E, et al. Anxiety and the risk of death in older men and women. Br J Psychiatry. 2004;185:399-404.
48. Curtis LH, Ostbye T, Sendersky V, et al. Inappropriate prescribing for elderly Americans in a large outpatient population. Arch Intern Med. 2004;164:1621-1625.
49. Madhusoodanan S, Bogunovic OJ. Safety of benzodiazepines in the geriatric population. Expert Opin Drug Saf. 2004;3:485-493.
50. Petrovic M, Mariman A, Warie H, Afschrift M, Pevernagie D. Is there a rationale for prescription of benzodiazepines in the elderly? Review of the literature. Acta Clin Belg. 2003;58:27-36.
51. Ashton H. Guidelines for the rational use of benzodiazepines. When and what to use. Drugs. 1994;48:25-40.
52. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716-2724.
53. Mort JR, Aparasu RR. Prescribing of psychotropics in the elderly: why is it so often inappropriate. CNS Drugs. 2002;16:99-109.
54. National Committee for Quality Assurance. Health Plan Employer Data and Information Set (HEDIS) 2006 Volume 2, Technical Specifications. 170-172.
55. Centers for Medicare and Medicaid Services (CMS). The Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Available at: www.cms.hhs.gov/medicarereform/MMActFullText.pdf. Accessed August 10, 2005.
56. Keene MS, Eaddy M, Nelson WW, Sarnes M. Adherence to paroxetine CR compared with paroxetine IR in a Medicare-eligible population with anxiety disorders. Am J Manag Care. 2005;11:S362-S369.
57. Panzer PE, Regan TS, Chiao E, et al. Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders. Am J Manag Care. 2005;11:S370-S379.